The Bulletin

The Morning Briefing: Drug regulation

Posting in Cancer

"The Morning Briefing" is SmartPlanet's daily roundup of must-reads from the web. This morning we're reading about drug regulation.

1.) Ministerial panel recommends price control for 348 essential drugs. A panel of ministers has recommended price regulation for 348 drugs deemed essential, up from 74 earlier, a minister said, a move that is likely to hit prices of costly brands sold by domestic as well as multi-national drugmakers.

2.) Lawmakers seek more regulation of compounded drugs. Two Democratic lawmakers on Tuesday called for stricter federal oversight of compounding pharmacies in the wake a deadly meningitis outbreak linked to contaminated injections made by a Massachusetts specialty pharmacy.

3.) Accountability probe could lead to regulation for managers. The government signalled a possible move towards the regulation of NHS managers as new health secretary Jeremy Hunt launched a probe to determine how they might be held to account for care failures.

4.) Steroid scare: A deadly outbreak shows a need for Pa. regulation. In this political open season on regulations, the public health arena has served up a tragic reminder of why governments have an obligation to set rules on the making and marketing of products that can cause harm as well as good.

5.) Court upholds abortion drug regulation. The Sixth U.S. Circuit Court of Appeals has upheld an Ohio law related to RU-486, leaving only one issue to be decided. The court ruled that The Buckeye State has the right to regulate use of the drug.

Image credit: e-Magine


— By on October 9, 2012, 6:00 PM PST

Charlie Osborne

Contributing Editor

Charlie Osborne is a freelance journalist and photographer based in London. In addition to SmartPlanet, she also writes for business technology website ZDNet and consumer technology site CNET. She holds a degree in medical anthropology from the University of Kent. Follow her on Twitter. Disclosure